Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
38%
Overall Survival
27%
Chronic Graft-versus-host Disease (cGVHD)
25%
Meta-analysis
24%
Graft-versus-host Disease (GvHD)
23%
Working Party
21%
Relapsed/refractory
20%
Multiple Myeloma
18%
Hematopoietic Cell Transplantation
18%
Marrow Transplantation
14%
Blood Transplantation
14%
Acute Leukemia
14%
Single-center Experience
14%
Transplantation
13%
European Society
12%
Oncology Patients
12%
Venetoclax
11%
Infectious Diseases
11%
Relative Risk
11%
Hematopoietic Stem Cell Transplantation
11%
Reduced-intensity Conditioning
10%
Israel
9%
Allogeneic Transplantation
9%
First Complete Remission
9%
Complete Remission
9%
Large B-cell Lymphoma
9%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Risk Factors
9%
Chemotherapy
9%
Hematopoietic Stem Cell Transplant Recipients
8%
95% Confidence Interval
8%
Lymphoma
8%
Allogeneic
8%
Elderly Patients
8%
Leukemia Patients
8%
Hazard Ratio
8%
Autologous Stem Cell Transplantation (auto-SCT)
8%
Non-relapse Mortality
8%
Methotrexate
8%
Randomized Controlled Trial
7%
High Risk
7%
Stem Cell Transplantation
7%
Conditioning Regimen
7%
FLT3 mutation
7%
Gilteritinib
6%
Busulfan
6%
Donor Lymphocyte Infusion
6%
Non-Hodgkin Lymphoma
6%
FLAG-Ida
6%
Medicine and Dentistry
Hematopoietic Cell
48%
Cell Transplantation
41%
Acute Myeloid Leukemia
28%
Allogeneic Hematopoietic Stem Cell Transplantation
22%
Overall Survival
21%
Multiple Myeloma
21%
Graft Versus Host Reaction
18%
Allogeneic Stem Cell Transplantation
14%
Diseases
12%
Systematic Review
12%
Infection
11%
Chemotherapy
10%
Reduced Intensity Conditioning
10%
Meta-Analysis
9%
Stem Cell Therapy
9%
Autologous Stem Cell Transplantation
9%
Acute Leukemia
8%
Busulfan
8%
Elderly Patient
8%
Median Follow Up
7%
Retrospective Study
7%
Drug Megadose
7%
Diffuse Large B-Cell Lymphoma
7%
Hematopoietic Stem Cell Transplantation
7%
Venetoclax
6%
Large-Cell Lymphoma
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Donor Lymphocyte Infusion
6%
Non-Hodgkin Lymphoma
6%
Progression Free Survival
6%
Allograft
6%
Acute Myelogenous Leukemia
5%
Hematologic Malignancy
5%
Hazard Ratio
5%
Salvage Therapy
5%
Immunology and Microbiology
Hematopoietic Cell
64%
Cell Transplantation
56%
Graft-Versus-Host Disease
36%
Infectious Disease
30%
Infection
30%
Myeloid
26%
Overall Survival
17%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Allograft
14%
Multiple Myeloma
11%
Chronic Graft Versus Host Disease
10%
Methotrexate
10%
Lymphocyte
9%
Engraftment
9%
Allogeneic Stem Cell Transplantation
8%
Hematopoietic Stem Cell Transplantation
8%
Drug Megadose
7%
Cytomegalovirus
6%
Acute Graft Versus Host Disease
6%
Neutrophil
6%
B Cell
5%
Progression Free Survival
5%